Five antiangiogenic drugs are recommended as initial treatment of metastatic renal cell carcinoma patients.
•
Sunitinib, pazopanib, axitinib and bevacizumab + interferon alpha-2a yield a similar survival benefit but have different safety profiles.
•
These results may provide guidance to optimize treatment choices.
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.